Filing Flows › United Therapeutics (UTHR) › Remodulin revenue
United Therapeutics (UTHR) Remodulin revenue by quarter
United Therapeutics' Remodulin revenue was $122M in Q3 2026 (third quarter 2026), -3% from Q2 2026. Over the last 7 quarters it ranged from $122M (Q3 2026) to $138M (Q1 2025).
| Quarter | Remodulin revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $122M | -3% | -3% |
| Q2 2026 | $126M | -0.2% | -6% |
| Q1 2026 | $127M | -1% | -8% |
| Q4 2025 | $128M | +2% | — |
| Q3 2025 | $126M | -7% | — |
| Q2 2025 | $135M | -3% | — |
| Q1 2025 | $138M | — | — |
Q3 2026 at a glance
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
Questions
What is United Therapeutics' Remodulin revenue?
United Therapeutics' Remodulin revenue was $122M in Q3 2026 (third quarter 2026), -3% from Q2 2026.
How has United Therapeutics' Remodulin revenue changed?
Over the last 7 quarters it ranged from $122M (Q3 2026) to $138M (Q1 2025).